BIAF
What one share of bioAffinity Technologies holds
Services – Commercial Physical and Biological Research
bioAffinity Technologies’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $1.55 |
|---|---|
| Profit | −$3.98 |
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$3.03 |
| Cash and investments | $0.36 |
| Debt | $0.01 |
| Book value | $0.56 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | — | −$70.94 | — | −$22.98 | — | −$176.95 |
| 2022 | $46.01 | −$54.37 | $1.47 | −$28.61 | — | $39.53 |
| 2023 | $27.09 | −$27.22 | $0.08 | −$20.79 | — | $15.50 |
| 2024 | $23.16 | −$22.37 | $0.20 | −$18.17 | — | $5.01 |
| 2025 | $3.58 | −$8.66 | $0.04 | −$5.46 | — | $1.62 |